Company Description
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States.
The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors.
The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma.
Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.
| Country | United States |
| Founded | 2018 |
| IPO Date | Sep 15, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 87 |
| CEO | Todd Harris |
Contact Details
Address: 2656 State Street Carlsbad, California 92008 United States | |
| Phone | 619 728 4760 |
| Website | tyra.bio |
Stock Details
| Ticker Symbol | TYRA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001863127 |
| CUSIP Number | 90240B106 |
| ISIN Number | US90240B1061 |
| Employer ID | 83-1476348 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Todd Harris Ph.D. | Co-Founder, Chief Executive Officer, President and Director |
| Bhavesh Ashar M.B.A. | Chief Operating Officer |
| Dr. Douglas Warner M.D. | Chief Medical Officer |
| Daniel Bensen | Co-Founder and Chief Discovery Officer |
| Julia Rueb | Vice President of Finance and Principal Accounting Officer |
| Ali D. Fawaz J.D. | General Counsel and Secretary |
| Sarah Honig | Senior Vice President of Corporate Development and Strategy |
| Liz Pagano | Chief Human Resources Officer |
| Erik Goluboff M.D. | Senior Vice President of Clinical Development |
| Dr. Ralph William Charlton III, M.D. | Senior Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2026 | SCHEDULE 13G/A | Filing |
| Apr 17, 2026 | ARS | Filing |
| Apr 17, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 17, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 17, 2026 | 8-K | Current Report |
| Apr 13, 2026 | 144 | Filing |
| Apr 7, 2026 | SCHEDULE 13G | Filing |
| Apr 2, 2026 | 8-K | Current Report |
| Mar 26, 2026 | 144 | Filing |
| Mar 25, 2026 | 144 | Filing |